Axsome to send Alzheimer’s disease drug to FDA, despite mixed …
5 天之前 · Axsome Therapeutics is moving ahead with plans to submit its Alzheimer’s disease treatment for Food and Drug Administration approval despite mixed results from two new …
Axsome to seek approval of AXS-05 to treat agitation in Alzheimer's disease
1 天前 · The results from ACCORD-2 are largely consistent with an earlier study called ACCORD (NCT04797715) that also showed AXS-05 was better than a placebo at preventing agitation …
Axsome Posts Mixed Phase III Data in Alzheimer’s Agitation
2 天之前 · Axsome Therapeutics said Monday it plans to seek FDA approval in Alzheimer’s disease agitation despite seeing mixed results in late-phase studies. The biotech reported data …
Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite …
6 天之前 · Agitation caused by Alzheimer’s disease currently has one FDA-approved therapy, but that drug brings serious safety risks. An Axsome Therapeutics drug has mixed results from its …
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees
5 天之前 · In the clinical program for AXS-05 in Alzheimer's disease agitation, there have been no deaths in subjects receiving AXS-05. Axsome plans to submit an NDA for AXS-05 in …
Axsome to seek approval for Alzheimer's-related agitation drug …
5 天之前 · Dec 30 (Reuters) - Axsome Therapeutics (AXSM.O), opens new tab said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with …
Axsome Therapeutics Announces Successful Completion and
5 天之前 · AXS-05 substantially and statistically significantly prevented worsening of severity of Alzheimer's disease overall as compared to placebo, with 13.3% of AXS-05 patients …
Axsome Therapeutics Announces Successful Completion and …
5 天之前 · Axsome Therapeutics, Inc. ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)
Axsome Therapeutics Announces Successful Completion and …
5 天之前 · AXS-05 substantially and statistically significantly prevented worsening of severity of Alzheimer's disease overall as compared to placebo, with 13.3% of AXS-05 patients …
Axsome Therapeutics Reports Positive Results from ACCORD-2
5 天之前 · AXS-05 substantially and statistically significantly prevented worsening of severity of Alzheimer's disease overall as compared to placebo, with 13.3% of AXS-05 patients …
- 某些结果已被删除